ZBIO — Zenas BioPharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1953926 ·
Last close
$26.95
Market Cap
$1.76B
52W High
$44.60
52W Low
$13.50
ADV30
738,410
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | -77,659,000 | — | — | — | — |
| Mar 2026 | 0 | — | -77,350,000 | -80,987,000 | 747,682,000 | 500,224,000 | 411,853,000 |
| Dec 2025 | 0 | — | -71,312,000 | -240,442,000 | 383,640,000 | 110,641,000 | 141,496,000 |
| Sep 2025 | 0 | — | -47,580,000 | -51,499,000 | 322,018,000 | 115,565,000 | 125,590,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-210,478,000
Investing CF
$-134,001,000
Financing CF
$648,660,000
CapEx
$-35,020,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.47
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-846,115,000
Inventory
—
Receivables
—
ST Investments
$216,981,000
EBIT TTM
$-407,515,000
Pretax Income TTM
$-425,025,000
Interest Exp TTM
$6,631,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,000,000
EBITDA
$-273,870,016
Free Cash Flow
$-211,391,632
Enterprise Value
$1,683,034,624
Total Cash
$643,126,016
Total Debt
$297,860,992
Shares Out
65,176,723
Trailing EPS
$-9.63
Book Value
$3.90
ROE
-199.0%
ROA
-34.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,000,000 | -211,385,000 | -377,737,000 | 383,640,000 | 141,496,000 | 242,144,000 | -172,333,000 |
| Dec 2024 | 5,000,000 | -163,888,000 | -156,988,000 | 369,968,000 | 57,510,000 | 312,458,000 | -119,674,000 |
| Dec 2023 | 50,000,000 | -27,147,000 | -37,124,000 | 68,180,000 | 293,901,000 | -225,721,000 | -30,529,000 |
| Dec 2022 | 0 | -75,199,000 | -119,282,000 | 74,579,000 | 266,865,000 | -192,286,000 | -65,652,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.66
Max Pain — expiry 2027-12-17
max pain strike: $20.00 · spot: $27.61 · call oi: 1,137 · put oi: 4,137
Expected Move to 2027-12-17:
±$17.50
(63.38%) —
implied range
$10.11 –
$45.11
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SEPN | Septerna, Inc. | $1.76B | $37.77 | — |
| XNCR | Xencor Inc | $1.77B | $23.80 | — |
| CMPS | COMPASS Pathways plc | $1.81B | $13.06 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.70B | $74.00 | — |
| NBTX | Nanobiotix S.A. | $1.69B | $33.31 | — |
News headlines (Yahoo Finance, 1h cache)
Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?
2026-09-23 11:14 · Yahoo
Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves?
2026-09-23 04:32 · Yahoo
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
2026-09-22 11:05 · Yahoo
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-18 20:15 · Yahoo
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
2026-09-04 11:05 · Yahoo
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
2026-07-17 12:13 · Yahoo
Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
2026-07-10 13:58 · Yahoo
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
2026-06-21 11:31 · Yahoo
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
2026-06-11 20:15 · Yahoo
Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Publis
2026-06-02 23:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.